Shots:
- Sanofi has entered into an agreement to acquire Vigil Neuroscience incl. its asset VG-3927 (TREM2 agonist), strengthening its neurology pipeline; Vigil’s VGL101 program is not a part of the acquisition
- As per the deal, Sanofi will acquire Vigil for ~$470M, with shareholders receiving $8/share in cash & a non-transferable CVR of $2/share payable upon the first commercial sale of VG-3927; closing expected in Q3’25
- In Jun 2024, Sanofi invested $40M in Vigil, securing exclusive first negotiation rights for exclusive license, grant, or transfer of rights to research, develop, manufacture, & commercialize VG-3927, which is to advance in P-II trial for Alzheimer’s disease
Ref: Sanofi| Image: Vigil Neuroscience| Press Release
Related News:- Viz.ai Enters a Multi-Year Partnership with Sanofi and Regeneron to Improve Management and Care of COPD
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
